Start Time: 08:30 January 1, 0000 9:03 AM ET

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)
Q2 2024 Earnings Conference Call
August 08, 2024, 08:30 AM ET

Company Participants

John Shannon - CEO
Steven Pieper - CFO
Allison Wey - SVP, IR and Corporate Communications

Conference Call Participants

Roanna Ruiz - Leerink Partners
Chase Knickerbocker - Craig-Hallum
Rohan Mathur - Oppenheimer

Operator

Hello, everyone, and welcome to today's Xeris Biopharma Second Quarter 2024 Financial Results Call. My name is Drew, and I'll be your operator today. During today's call there will be a Q&A session. [Operator Instructions].

I will now turn the call over to Allison Wey, Senior Vice President of Investor Relations and Corporate Communication to begin. Please go ahead.

Allison Wey

Thank you, Drew. Good morning and welcome to Xeris Biopharma's second quarter and first half 2024 financial results conference call and webcast. This morning, we issued our press release which can be found on our website. We're joined this morning by John Shannon, our new CEO; and Steve Pieper, our CFO. After our prepared remarks, we will open the lines for questions.

Before we begin, I would like to remind you that this call will contain forward-looking statements concerning the company's future expectations, plans, prospects and financial performance. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those forward-looking statements.

For more information on such risks, please refer to our earnings release and risk factors included in our SEC filings. Any forward-looking statements in this call represent our views only as of the date of this call and subject to applicable law, we disclaim any obligations to update such statements.

I will now turn the call over to John Shannon.

John Shannon

Thank you, Allison, and good morning, everyone. I'm honored to speak with you for the first time as the CEO of Xeris. It's an exciting time for our company as we start this new era and I'm thrilled to serve in this role. As you all saw from this morning's earnings release, we had an outstanding second quarter. But before we get into the results, I want to take a moment to outline my near-term priorities as the new CEO.

I'm focused on three key priorities to guide our strategic initiatives and decision-making processes in the near term. These represent important opportunities for creating value for our stakeholders. The first priority is maintaining rapid commercial growth and expanding the reach of our treatments to the patient communities they serve.